Although the malignancies reported in these trials are rare, comparing patients treated with anti-TNF therapies versus patients receiving methotrexate or no disease-modifying antirheumatic drugs suggested an increased risk of hematological malignancies in anti-TNF treated patients [8]. This evidence concerns the gene TNF and hematologic disorder.